Exclusive Online Content
Tarsus Completes Enrollment for the Pivotal Phase 3 Saturn-2 Trial of TP-03 to Treat Demodex Blepharitis & Secures $175 Million Credit Facility
Tarsus Pharmaceuticals, Inc. recently announced it has completed enrollment of Saturn-2, the company’s second pivotal Phase 3 trial of TP-03 (lotilaner ophthalmic solution, 0.25%) for patients with….
Brickell Biotech Acquires Exclusive Global Rights to Portfolio of Novel STING Inhibitors Targeting Autoimmune & Inflammatory Diseases from Carna Biosciences
Brickell Biotech, Inc. and Carna Biosciences, Inc. recently announced they have entered into a licensing agreement, whereby Brickell will have the exclusive, worldwide rights to develop and commercialize….
Evoke Pharma & EVERSANA Extend Commercialization Partnership to Further Support GIMOTI
Evoke Pharma, Inc. and EVERSANA Life Science Services, LLC recently announced the extension of their agreement to continue collaborating on the commercialization and distribution of….
Syner-G BioPharma Group Acquires IMPACT; Expands Services for Biotech & Pharma Copanies
Syner-G BioPharma Group recently announced the acquisition of Impact Pharmaceutical Services (IMPACT). Based in Research Triangle Park, NC, IMPACT supports the….
MaxCyte Signs Strategic Platform License With Intima Bioscience to Advance Tumor Infiltrating Lymphocytes Programs
MaxCyte, Inc. recently announced the signing of a strategic platform license (SPL) with Intima Bioscience, Inc., a clinical stage biotechnology company developing genetically engineered cell….
ANAVEX2-73 (Blarcamesine) AVATAR Phase 3 Trial Met Primary & Secondary Efficacy Endpoints for the Treatment of Adult Patients With Rett Syndrome
Anavex Life Sciences Corp. recently reported positive top-line results from the Phase 3 randomized, double-blind, placebo-controlled AVATAR trial of ANAVEX2-73 (blarcamesine) in adult female….
Arcutis Completes Enrollment of STRATUM Pivotal Phase 3 Trial of Topical Roflumilast Foam in Individuals With Seborrheic Dermatitis
Arcutis Biotherapeutics, Inc. recently announced the enrollment of the last subject in its STRATUM Phase 3 pivotal trial for topical roflumilast foam in patients with….
Veru Enters Clinical Trial Collaboration & Supply Agreement With Eli Lilly & Company
Veru Inc. recently announced it has entered into a clinical trial collaboration and supply agreement with Eli Lilly and Company. The objective of the collaboration is to evaluate the efficacy and safety of….
Aravive Announces First Patient Dosed in Phase 2 Study of Batiraxcept in Clear Cell Renal Cell Carcinoma
Aravive, Inc. recently announced it has dosed the first patient in the Phase 2 portion of the Phase 1b/2 study of batiraxcept for the treatment of clear cell renal cell carcinoma (ccRCC)…..
Celsion Corporation Advances Proof of Concept to Non-human Primate Challenge Study Against SARS-CoV-2 With In-Process Vaccine Candidate
Celsion Corporation recently announced it has engaged BIOQUAL, Inc., a preclinical testing contract research organization, to conduct a non-human primate (NHP) challenge study with Celsion’s DNA-based approach for….
Biogen Reaches Agreement With Samsung Biologics to Sell Equity Stake in Their Biosimilar Joint Venture for up to $2.3 Billion
Biogen Inc. recently announced it has entered into an agreement whereby Samsung Biologics will acquire Biogen’s equity stake in the Samsung Bioepis joint venture for an aggregate consideration of up to….
Maravai LifeSciences Acquires MyChem, a Leader in Proprietary Ultra-Pure Nucleotides
Maravai LifeSciences, Inc. recently announced it has acquired MyChem, LLC for $240 million in cash at closing with the potential for additional contingent cash consideration based on achievement of….
Enable Injections Announces $215-Million Financing
Enable Injections, Inc. recently announced $215 million in Series C financing. Magnetar Capital (Magnetar) led the financing along with new institutional investments from….
Recipharm Secures Vaccine Manufacturing Deal
Global contract development and manufacturing organization (CDMO), Recipharm, has recently inked a deal with a top 10 big pharma company to support vaccine manufacturing from its….
Cocrystal Pharma Selects Two Lead Antiviral Drug Candidates for its COVID-19 Oral Drug Program
Cocrystal Pharma, Inc. has selected two investigational novel antiviral drug candidates for further development as oral treatments for SARS-CoV-2, the virus that causes COVID-19…..
PDS Biotech Announces Preclinical Data for PDS0202 Universal Influenza Vaccine
PDS Biotechnology Corporation recently announced preclinical data for its universal flu vaccine, which was shown to be effective against….
Evaxion Biotech Announces Publication of Clinical Data of EVX-01 Heading Into Phase 2b in Collaboration With Merck
Evaxion Biotech A/S recently announced the publication of a paper on personalized therapy with EVX-01 in patients with metastatic melanoma in the open access, peer-reviewed….
Hepion Pharmaceuticals’ Rencofilstat, in Combination With an Immune Checkpoint Inhibitor, Demonstrates Synergistic Anti-Tumor Activity in a Nonclinical Liver Cancer Study
Hepion Pharmaceuticals, Inc. recently announced the results of a nonclinical research study showing that its clinical phase drug candidate, rencofilstat (CRV431), synergistically decreased liver tumor….
Athira Pharma Announces Initiation of Patient Dosing in SHAPE, a Phase 2 Clinical Trial of ATH-1017 for the Treatment of Parkinson's Disease Dementia & Dementia with Lewy Bodies
Athira Pharma, Inc. recently announced patient dosing has begun in SHAPE, a Phase 2 clinical trial of ATH-1017 for the treatment of Parkinson’s disease dementia and Dementia with Lewy bodies….
Biomea Fusion Announces First Patient Dosed
Biomea Fusion, Inc. recently announced the first patient has been dosed in its Phase 1 clinical trial evaluating BMF-219, the company’s irreversible covalent menin inhibitor, in patients with….
